85 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Chaves-Moreira D, Mitchell MA, Arruza C, Rawat P, Sidoli S, Nameki R, Reddy J, Corona RI, Afeyan LK, Klein IA, Ma S, Winterhoff B, Konecny GE, Garcia BA, Brady DC, ... ... Drapkin R, et al. The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17. Science Signaling. 15: eabm2496. PMID 35380877 DOI: 10.1126/scisignal.abm2496  0.408
2021 Cunningham JM, Winham SJ, Wang C, Weigelt B, Fu Z, Armasu SM, McCauley BM, Brand AH, Chiew YE, Elishaev E, Gourley C, Kennedy CJ, Laslvic A, Lester J, Piskorz A, ... ... Drapkin R, et al. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34697060 DOI: 10.1158/1055-9965.EPI-21-0677  0.303
2021 Xu H, George E, Kinose Y, Kim H, Shah JB, Peake JD, Ferman B, Medvedev S, Murtha T, Barger CJ, Devins KM, D'Andrea K, Wubbenhorst B, Schwartz LE, Hwang WT, ... ... Drapkin R, et al. copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Reports. Medicine. 2: 100394. PMID 34622231 DOI: 10.1016/j.xcrm.2021.100394  0.35
2021 Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, Liu H, Fatkhutdinov N, Zundell JA, Karakashev S, Zhou W, Schwartz LE, Tang HY, Drapkin R, Liu Q, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer. 2: 189-200. PMID 34085048 DOI: 10.1038/s43018-020-00160-x  0.332
2021 Gysler SM, Drapkin R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. The Journal of Clinical Investigation. 131. PMID 34060481 DOI: 10.1172/JCI147276  0.315
2021 Barger CJ, Chee L, Albahrani M, Munoz-Trujillo C, Boghean L, Branick C, Odunsi K, Drapkin R, Zou L, Karpf AR. Co-regulation and function of / bidirectional genes in cancer. Elife. 10. PMID 33890574 DOI: 10.7554/eLife.55070  0.428
2021 Mauro LJ, Seibel MI, Diep CH, Spartz A, Perez Kerkvliet C, Singhal H, Swisher EM, Schwartz LE, Drapkin R, Saini S, Sesay F, Litovchick L, Lange CA. Progesterone Receptors Promote Quiescence & Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models. The Journal of Clinical Endocrinology and Metabolism. PMID 33755733 DOI: 10.1210/clinem/dgab195  0.318
2021 Tangri A, Lighty K, Loganathan J, Mesmar F, Podicheti R, Zhang C, Iwanicki M, Drapkin R, Nakshatri H, Mitra S. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research : McR. PMID 33753553 DOI: 10.1158/1541-7786.MCR-20-0883  0.361
2021 Burston HE, Kent OA, Communal L, Udaskin ML, Sun RX, Brown KR, Jung E, Francis KE, La Rose J, Lowitz JK, Drapkin R, Mes-Masson AM, Rottapel R. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. The Journal of Clinical Investigation. PMID 33561012 DOI: 10.1172/JCI142677  0.385
2021 Ferrari AJ, Drapkin R, Gogna R. Cell Fitness: More Than Push-Ups. International Journal of Molecular Sciences. 22. PMID 33430180 DOI: 10.3390/ijms22020518  0.363
2021 Chaves-Moreira D, Morin PJ, Drapkin R. Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers. Cancer Research. 81: 806-810. PMID 33361393 DOI: 10.1158/0008-5472.CAN-20-3173  0.431
2020 Lv X, He C, Huang C, Hua G, Chen X, Timm BK, Maclin VM, Haggerty AA, Aust SK, Golden DM, Dave BJ, Tseng YA, Chen L, Wang H, Chen P, ... ... Drapkin RI, et al. Reprogramming of Ovarian Granulosa Cells by YAP1 Leads to Development of High-Grade Cancer with Mesenchymal Lineage and Serous Features. Science Bulletin. 65: 1281-1296. PMID 34888112 DOI: 10.1016/j.scib.2020.03.040  0.432
2020 Pierini S, Tanyi JL, Simpkins F, George E, Uribe-Herranz M, Drapkin R, Burger R, Morgan MA, Facciabene A. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. Jci Insight. 5. PMID 32814714 DOI: 10.1172/jci.insight.136773  0.311
2020 Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, ... ... Drapkin R, et al. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. Plos Genetics. 16: e1008808. PMID 32497036 DOI: 10.1371/Journal.Pgen.1008808  0.415
2020 Suryo Rahmanto Y, Shen W, Shi X, Chen X, Yu Y, Yu ZC, Miyamoto T, Lee MH, Singh V, Asaka R, Shimberg G, Vitolo MI, Martin SS, Wirtz D, Drapkin R, et al. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nature Communications. 11: 2717. PMID 32483112 DOI: 10.1038/S41467-020-16416-0  0.361
2020 Ding B, Yuan F, Damle PK, Litovchick L, Drapkin R, Grossman SR. CtBP determines ovarian cancer cell fate through repression of death receptors. Cell Death & Disease. 11: 286. PMID 32332713 DOI: 10.1038/S41419-020-2455-7  0.388
2020 Reavis HD, Drapkin R. The tubal epigenome - An emerging target for ovarian cancer. Pharmacology & Therapeutics. 210: 107524. PMID 32197795 DOI: 10.1016/j.pharmthera.2020.107524  0.401
2020 Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearce OMT, Hirani P, Joy JD, Szabova L, Perets R, Sansom OJ, ... Drapkin R, et al. Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment. Cell Reports. 30: 525-540.e7. PMID 31940494 DOI: 10.1016/j.celrep.2019.12.034  0.329
2019 Lawrenson K, Fonseca MAS, Liu AY, Segato Dezem F, Lee JM, Lin X, Corona RI, Abbasi F, Vavra KC, Dinh HQ, Gill NK, Seo JH, Coetzee S, Lin YG, Pejovic T, ... ... Drapkin R, et al. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development. Cell Reports. 29: 3726-3735.e4. PMID 31825847 DOI: 10.1016/J.Celrep.2019.10.122  0.329
2019 Bai S, Zhu W, Coffman L, Vlad A, Schwartz LE, Elishaev E, Drapkin R, Buckanovich RJ. CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary. Cancers. 11. PMID 31684072 DOI: 10.3390/Cancers11111710  0.301
2019 Reavis H, Drapkin R. H2Bub1: Guardian of chromatin accessibility in ovarian cancer. Oncoscience. 6: 349-350. PMID 31608296 DOI: 10.18632/oncoscience.484  0.377
2019 Chui MH, Doodnauth SA, Erdmann N, Tiedemann RE, Sircoulomb F, Drapkin R, Shaw P, Rottapel R. Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma. Cancer Research. PMID 31530568 DOI: 10.1158/0008-5472.Can-18-3029  0.382
2019 Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, et al. ARID1A promotes genomic stability through protecting telomere cohesion. Nature Communications. 10: 4067. PMID 31492885 DOI: 10.1038/S41467-019-12037-4  0.355
2019 Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. PMID 30835824 DOI: 10.1002/Cncr.32004  0.352
2018 Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, Song M, Hirsch MS, Lester J, Parkash V, Karlan BY, Oren M, Hoon DS, Drapkin R. Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Research. PMID 30563893 DOI: 10.1158/0008-5472.Can-18-2297  0.334
2018 Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, et al. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports. 25: 2617-2633. PMID 30485824 DOI: 10.1016/J.Celrep.2018.10.096  0.399
2018 Barger CJ, Zhang W, Sharma A, Chee L, James SR, Kufel CN, Miller A, Meza J, Drapkin R, Odunsi K, Klinkebiel D, Karpf AR. Expression of the POTE gene family in human ovarian cancer. Scientific Reports. 8: 17136. PMID 30459449 DOI: 10.1038/s41598-018-35567-1  0.366
2018 Elias KM, Tsantoulis P, Tille JC, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Puppa G, Stuckelberger S, Hooda J, Dietrich PY, Goggins M, Kerr CL, ... ... Drapkin R, et al. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. The Journal of Pathology. PMID 30229909 DOI: 10.1002/path.5161  0.318
2018 Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, ... Drapkin R, et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology. PMID 29572027 DOI: 10.1016/J.Ygyno.2018.03.050  0.324
2018 Stuckelberger S, Drapkin R. Precious GEMMs: emergence of faithful models for ovarian cancer research. The Journal of Pathology. 245: 129-131. PMID 29493783 DOI: 10.1002/path.5065  0.371
2018 Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nature Communications. 9: 631. PMID 29434212 DOI: 10.1038/S41467-018-03031-3  0.415
2017 Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, ... ... Drapkin R, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications. 8: 1093. PMID 29061967 DOI: 10.1038/S41467-017-00962-1  0.371
2017 Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Communications. 8: 365. PMID 28848242 DOI: 10.1038/S41467-017-00263-7  0.324
2017 Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, ... ... Drapkin R, et al. PRKCI promotes immune suppression in ovarian cancer. Genes & Development. PMID 28698296 DOI: 10.1101/Gad.296640.117  0.424
2017 Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, et al. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016703439. PMID 28398847 DOI: 10.1200/Jco.2016.70.3439  0.355
2017 Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, Sircoulomb F, Krzyzanowski P, Novak M, Doodnauth SA, Saiz FS, Cullis J, Al-Awar R, Neel BG, McPherson J, ... Drapkin R, et al. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Reports. 18: 2343-2358. PMID 28273451 DOI: 10.1016/J.Celrep.2017.02.028  0.31
2017 George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, ... ... Drapkin R, et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. Jci Insight. 2: e89760. PMID 28097235 DOI: 10.1172/Jci.Insight.89760  0.377
2017 Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Current Opinion in Obstetrics & Gynecology. 29: 26-34. PMID 27898521 DOI: 10.1097/GCO.0000000000000340  0.394
2016 Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD. Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663592 DOI: 10.1158/1078-0432.CCR-16-0620  0.327
2016 Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, MacDuffie E, Davis MR, Holman A, Lawney B, Freedman ML, Quackenbush J, Brown M, Drapkin R. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. Jci Insight. 1. PMID 27617304 DOI: 10.1172/Jci.Insight.87988  0.543
2016 Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, ... ... Drapkin R, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27573169 DOI: 10.1158/1078-0432.Ccr-16-1237  0.548
2016 Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Science Translational Medicine. 8: 329ra34. PMID 26962158 DOI: 10.1126/Scitranslmed.Aad5653  0.353
2015 Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... ... Drapkin RI, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047  0.436
2015 Feng Y, Doberstein K, Drapkin R. Elafin: a double agent in breast and ovarian cancer. Oncoscience. 2: 793-4. PMID 26682248  0.395
2015 Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer. 15: 668-79. PMID 26493647 DOI: 10.1038/Nrc4019  0.362
2015 Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecologic Oncology. 139: 97-103. PMID 26321251 DOI: 10.1016/J.Ygyno.2015.08.017  0.304
2015 Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, Skates S, Birrer M. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4960-9. PMID 25944803 DOI: 10.1158/1078-0432.Ccr-14-3173  0.366
2015 Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Levanon K, Karst A, Drapkin R, Ramus SJ, Couch FJ, Offit K, Chenevix-Trench G, et al. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics. 24: 3595-607. PMID 25804953 DOI: 10.1093/Hmg/Ddv101  0.386
2015 Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 160: 977-89. PMID 25723171 DOI: 10.1016/J.Cell.2015.01.042  0.534
2015 Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 112: 232-7. PMID 25535366 DOI: 10.1073/Pnas.1422165112  0.659
2014 Emori MM, Drapkin R. The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reproductive Biology and Endocrinology : Rb&E. 12: 60. PMID 24997727 DOI: 10.1186/1477-7827-12-60  0.328
2014 Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. The Journal of Clinical Investigation. 124: 2611-25. PMID 24762435 DOI: 10.1172/Jci69815  0.435
2014 Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, ... ... Drapkin R, et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America. 111: 1102-7. PMID 24385586 DOI: 10.1073/Pnas.1311909111  0.449
2014 Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Research. 74: 1141-52. PMID 24366882 DOI: 10.1158/0008-5472.CAN-13-2247  0.304
2013 Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, ... Drapkin R, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 24: 751-65. PMID 24332043 DOI: 10.1016/j.ccr.2013.10.013  0.393
2013 Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, Drapkin R, Broaddus R, Dowdy S, Jiang SW. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. International Journal of Molecular Sciences. 14: 6026-43. PMID 23502467 DOI: 10.3390/ijms14036026  0.434
2013 Sung CK, Li D, Andrews E, Drapkin R, Benjamin T. Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. Molecular Oncology. 7: 419-27. PMID 23273547 DOI: 10.1016/J.Molonc.2012.11.005  0.317
2012 Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5806-15. PMID 22912389 DOI: 10.1158/1078-0432.Ccr-12-0857  0.331
2012 Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Science Translational Medicine. 4: 147ra112. PMID 22896676 DOI: 10.1126/Scitranslmed.3003778  0.422
2012 Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. Plos One. 7: e30269. PMID 22348002 DOI: 10.1371/Journal.Pone.0030269  0.441
2012 Vermeer PD, Bell M, Lee K, Vermeer DW, Wieking BG, Bilal E, Bhanot G, Drapkin RI, Ganesan S, Klingelhutz AJ, Hendriks WJ, Lee JH. ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers. Plos One. 7: e30447. PMID 22279592 DOI: 10.1371/Journal.Pone.0030447  0.329
2012 Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang SW, Podratz K, Urban N, Dowdy SC. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer Gynecologic Oncology. 124: 270-275. PMID 22037318 DOI: 10.1016/j.ygyno.2011.10.025  0.318
2011 Karst AM, Drapkin R. The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Medicine Reports. 3: 22. PMID 22076125 DOI: 10.3410/M3-22  0.324
2011 Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (New York, N.Y.). 334: 1129-33. PMID 22033517 DOI: 10.1126/Science.1206727  0.534
2011 Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews. Cancer. 11: 719-25. PMID 21941283 DOI: 10.1038/Nrc3144  0.315
2011 Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. Plos One. 6: e24433. PMID 21931712 DOI: 10.1371/Journal.Pone.0024433  0.372
2011 Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, ... ... Drapkin R, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 108: 12372-7. PMID 21746896 DOI: 10.1073/Pnas.1109363108  0.46
2011 Fotheringham S, Levanon K, Drapkin R. Ex vivo culture of primary human fallopian tube epithelial cells. Journal of Visualized Experiments : Jove. PMID 21610668 DOI: 10.3791/2728  0.448
2011 Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Frontiers in Bioscience (Elite Edition). 3: 625-34. PMID 21196340  0.31
2010 Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural & Molecular Biology. 17: 688-95. PMID 20453858 DOI: 10.1038/Nsmb.1831  0.456
2010 Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, ... ... Drapkin R, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 17: 298-310. PMID 20227043 DOI: 10.1016/J.Ccr.2009.12.047  0.611
2010 Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia (New York, N.Y.). 12: 161-72. PMID 20126474 DOI: 10.1593/NEO.91542  0.4
2009 Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 55: 619. PMID 19912369 DOI: 10.1111/j.1365-2559.2009.03408.x  0.358
2009 Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. Journal of Oncology. 2010: 932371. PMID 19746182 DOI: 10.1155/2010/932371  0.38
2008 Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6478-86. PMID 18927287 DOI: 10.1158/1078-0432.Ccr-08-1128  0.302
2008 Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact Journal of Clinical Oncology. 26: 5284-5293. PMID 18854563 DOI: 10.1200/JCO.2008.18.1107  0.336
2008 De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4672-80. PMID 18628483 DOI: 10.1158/1078-0432.CCR-08-0087  0.401
2007 Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clinical Medicine & Research. 5: 35-44. PMID 17456833 DOI: 10.3121/cmr.2007.702  0.394
2007 Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, Denunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell. 128: 991-1002. PMID 17350581 DOI: 10.1016/J.Cell.2007.02.025  0.663
2007 Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, ... ... Drapkin RI, et al. A recurrent mutation in PALB2 in Finnish cancer families Nature. 446: 316-319. PMID 17287723 DOI: 10.1038/Nature05609  0.574
2005 Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Research. 65: 2162-9. PMID 15781627 DOI: 10.1158/0008-5472.CAN-04-3924  0.306
2005 Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, Livingston DM, Rajewsky K. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes & Development. 19: 489-501. PMID 15713842 DOI: 10.1101/Gad.1248505  0.487
2004 Ganesan S, Silver DP, Drapkin R, Greenberg R, Feunteun J, Livingston DM. Association of BRCA1 with the inactive X chromosome and XIST RNA. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 359: 123-8. PMID 15065664 DOI: 10.1098/Rstb.2003.1371  0.7
2004 Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S, Livingston DM. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations Proceedings of the National Academy of Sciences of the United States of America. 101: 2357-2362. PMID 14983014 DOI: 10.1073/Pnas.0308717101  0.682
2002 Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, Rasmussen TP, Klimke A, Marrese C, Marahrens Y, Deng CX, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 111: 393-405. PMID 12419249 DOI: 10.1016/S0092-8674(02)01052-8  0.682
Show low-probability matches.